JOP20210274A1 - طرق لإعطاء مثبط vmat2 معين - Google Patents

طرق لإعطاء مثبط vmat2 معين

Info

Publication number
JOP20210274A1
JOP20210274A1 JOP/2021/0274A JOP20210274A JOP20210274A1 JO P20210274 A1 JOP20210274 A1 JO P20210274A1 JO P20210274 A JOP20210274 A JO P20210274A JO P20210274 A1 JOP20210274 A1 JO P20210274A1
Authority
JO
Jordan
Prior art keywords
administration
methods
vmat2 inhibitors
certain
certain vmat2
Prior art date
Application number
JOP/2021/0274A
Other languages
English (en)
Inventor
Dao Tuyet Thai-Cuarto
Grace S Liang
Barbara Scholz
Eiry W Roberts
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of JOP20210274A1 publication Critical patent/JOP20210274A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

غير متوفر
JOP/2021/0274A 2019-05-09 2020-05-08 طرق لإعطاء مثبط vmat2 معين JOP20210274A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962845599P 2019-05-09 2019-05-09
PCT/US2020/032188 WO2020227672A1 (en) 2019-05-09 2020-05-08 Methods for the administration of certain vmat2 inhibitors

Publications (1)

Publication Number Publication Date
JOP20210274A1 true JOP20210274A1 (ar) 2023-01-30

Family

ID=70919120

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0274A JOP20210274A1 (ar) 2019-05-09 2020-05-08 طرق لإعطاء مثبط vmat2 معين

Country Status (16)

Country Link
US (2) US20200397779A1 (ar)
EP (1) EP3965764A1 (ar)
JP (1) JP2022531696A (ar)
KR (1) KR20220007105A (ar)
CN (1) CN114340624A (ar)
AU (1) AU2020270145A1 (ar)
BR (1) BR112021020709A2 (ar)
CA (1) CA3136466A1 (ar)
EA (1) EA202193012A1 (ar)
IL (1) IL287902A (ar)
JO (1) JOP20210274A1 (ar)
MA (1) MA55893A (ar)
MX (1) MX2021013132A (ar)
SG (1) SG11202111465RA (ar)
TW (1) TW202108138A (ar)
WO (1) WO2020227672A1 (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230170135A (ko) 2017-01-27 2023-12-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
IL309802A (en) 2017-09-21 2024-02-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN116492340A (zh) 2017-10-10 2023-07-28 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
CA3104693A1 (en) 2018-08-15 2020-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
KR20240027780A (ko) * 2021-06-30 2024-03-04 뉴로크린 바이오사이언시즈 인코퍼레이티드 조현병의 부가적 치료에 사용하기 위한 발베나진
TW202322816A (zh) 2021-08-20 2023-06-16 美商紐羅克里生物科學有限公司 篩選 vmat2 抑制劑之方法
WO2023172849A1 (en) * 2022-03-07 2023-09-14 Neurocrine Biosciences, Inc. Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US952A (en) 1838-09-27 I antoni bengini
US10065A (en) 1853-10-04 Improvement in machines for topping cotton jn the field
EP4389227A2 (en) * 2014-05-06 2024-06-26 Neurocrine Biosciences, Inc. Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
KR20180015260A (ko) * 2015-06-23 2018-02-12 뉴로크린 바이오사이언시즈 인코퍼레이티드 신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제
KR20230170135A (ko) * 2017-01-27 2023-12-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
CA3104693A1 (en) * 2018-08-15 2020-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors

Also Published As

Publication number Publication date
IL287902A (en) 2022-01-01
MA55893A (fr) 2022-03-16
CN114340624A (zh) 2022-04-12
SG11202111465RA (en) 2021-11-29
US20200397779A1 (en) 2020-12-24
US20220040169A1 (en) 2022-02-10
WO2020227672A1 (en) 2020-11-12
MX2021013132A (es) 2021-11-25
KR20220007105A (ko) 2022-01-18
AU2020270145A1 (en) 2021-12-23
CA3136466A1 (en) 2020-11-12
EA202193012A1 (ru) 2022-03-02
BR112021020709A2 (pt) 2021-12-14
EP3965764A1 (en) 2022-03-16
JP2022531696A (ja) 2022-07-08
TW202108138A (zh) 2021-03-01

Similar Documents

Publication Publication Date Title
MX2021013132A (es) Metodos para la administracion de ciertos inhibidores del transportador 2 vesicular de monoaminas (vmat2).
MX2022000559A (es) Metodos para la administracion de ciertos inhibidores de vmat2 a pacientes con insuficiencia renal grave.
PH12021550302A1 (en) Methods for the administration of certain vmat2 inhibitors
PH12019501732A1 (en) Methods for the administration of certain vmat2 inhibitors
PH12020550237A1 (en) Methods for the administration of certain vmat2 inhibitors
NO20060416L (no) Ny anvendelse I
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
RS52945B (en) PHARMACEUTICAL FORMULATIONS AND THEIR APPLICATION IN THE TREATMENT OF WOMEN SEXUAL DYSFUNCTION
CR9694A (es) Inhibidores de la transcriptasa reversa de vih
YU10101A (sh) Prolekovi inhibitori proton pumpe
AR119158A1 (es) Tratamientos de angioedema hereditario
CR20220199A (es) Inhibidores del factor d del complemento para administración oral
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
CL2022000889A1 (es) Inhibidores del factor d del complemento para administración oral
MX2022008609A (es) Inhibidores de tgf¿ y uso de los mismos.
MX2019005723A (es) Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo.
WO2021239928A3 (en) Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
EA202190252A1 (ru) Способы введения определенных ингибиторов vmat2
MX2022001044A (es) Inhibidor de sglt2/dpp4 y su aplicacion.
CR20220565A (es) Inhibidores de il4i1 y métodos de uso
AR128051A1 (es) Inhibidores de parp1
JOP20210192A1 (ar) إكتشاف و تصميم مركبات جديدة لعلاج مرض فايروس كورونا المستجد لسنة 2019 (كوفيد-19)
WO2020101597A3 (en) Capsule compositions comprising tyrosine-kinase inhibitors